PubMed COVID-19 Clinical Care

INTRODUCTION/AIMS: In response to 2020 COVID-19 pandemic restrictions our face-to-face (F2F) multidisciplinary neuromuscular clinic (NMC) transitioned to widespread use of telehealth. This study aimed to 1) understand parent/guardian, child and

No abstract

One of the major virulence factors of SARS-CoV-2, NSP1, is a vital drug target due to its role in host immune evasion through multiple pathways. NSP1 protein is associated with inhibiting host mRNA translation by binding to the small subunit of

The novel Coronavirus Disease 2019 (COVID-19) is a global pandemic that has infected millions of people causing millions of deaths around the world. Reverse Transcription Polymerase Chain Reaction (RT-PCR) is the standard screening method for COVID

Autoimmune bullous diseases (AIBDs) are a heterogeneous group of diseases characterized by cutaneous and mucosal vesicles, blisters, and erosions. Several factors can trigger this disease, including vaccines; but this entity remains very rare. We

Teleworking has been growing over the decades, arising many challenges to overcome. The COVID-19 pandemic situation accelerated this process. The forms of presentation are varied, homework perhaps is the most frequent. The objective of this study was

CONCLUSION: It is crucial to encourage people to vaccinate in establishing immune barriers. Especially, when the supply is limit, a wiser strategy to restrict the SARS-CoV-2 transmission is equally distributing doses to the same amounts of

BACKGROUND: Novel SARS-CoV-2 variants of concern (VOC) Delta and Omicron are able to escape some monoclonal antibody therapies, making again COVID-19 convalescent plasma (CCP) a potential frontline treatment.

Background and aims Coronavirus disease 2019 (COVID-19) is caused by a virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first pandemic wave, SARS-CoV-2 had developed significant changes and mutations that

We identified a Delta-Omicron SARS-CoV-2 recombinant in an unvaccinated, immunosuppressed kidney transplant recipient who had positive COVID-19 tests in December 2021 and February 2022 and was initially treated with Sotrovimab. Viral sequencing in